Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling cell-free circulating nucleosomes. Nu.Q® Discover, a fee for service model, offers access to assays that provide Non-Invasive, Quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases.

Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with innate immune activation (NETosis) and epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi, SWI/SNF complex and more..). Nu.Q® assays effectively correlate with disease and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.